A vision of cell death: Fas ligand and immune privilege 10 years later.
about
The Cellular Prion Protein: A Player in Immunological QuiescenceMembrane trafficking of death receptors: implications on signallingApoptosis and the airway epitheliumFas/Fas ligand-mediated apoptosis in different cell lineages and functional compartments of human lymph nodesCytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.Targeting immune privilege to prevent pathogenic neovascularizationIn vivo emergence of HIV-1 highly sensitive to neutralizing antibodiesUnlike Th1, Th17 cells mediate sustained autoimmune inflammation and are highly resistant to restimulation-induced cell deathMechanisms of immune privilege in the posterior eye.Age-dependent changes in FasL (CD95L) modulate macrophage function in a model of age-related macular degenerationArmed response: how dying cells influence T-cell functions.Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.Suppressor of cytokine signaling-1 (SOCS1) inhibits lymphocyte recruitment into the retina and protects SOCS1 transgenic rats and mice from ocular inflammation.Fas/FasL pathway participates in regulation of antiviral and inflammatory response during mousepox infection of lungsIn vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression.A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival.Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases.Interleukin-10 promotes resolution of granulomatous experimental autoimmune thyroiditis.Endothelial Fas-Ligand in Inflammatory Bowel Diseases and in Acute Appendicitis.A role for collagen IV cross-links in conferring immune privilege to the Goodpasture autoantigen: structural basis for the crypticity of B cell epitopes.Increased resistance to Staphylococcus aureus endophthalmitis in BALB/c mice: Fas ligand is required for resolution of inflammation but not for bacterial clearance.DNA damage-induced cell death: lessons from the central nervous system.Adrenal-Derived Hormones Differentially Modulate Intestinal Immunity in Experimental ColitisShifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.FAS and FASL gene polymorphisms are not associated with hepatitis B virus infection based on a case-control study in a Brazilian population.Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations.Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives.Alterations in myocardial gene expression associated with experimental Trypanosoma cruzi infectionThe role of lymphocytes in the development and treatment of alopecia areata.Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2.Tuning cancer fate: the unremitting role of host immunity.Effects of intravitreally injected Fc fragment on rat eyes.Keynote lecture in the 13th Japanese Society of Immunotoxicology (JSIT 2006) : -Pathophysiological Development and Immunotoxicology: what we have found from research related to silica and silicate such as asbestos-.The retinal pigment epithelium (RPE) induces FasL and reduces iNOS and Cox2 in primary monocytes.Aqueous humor suppression of dendritic cell function helps maintain immune regulation in the eye during human uveitisSoluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.Serum apoptosis markers in HIV-infected patients with human herpesvirus type 8 and herpes simplex virus type 2 co-infection.Cytokines in Male Fertility and Reproductive Pathologies: Immunoregulation and Beyond.Association between FAS A670G polymorphism and susceptibility to cervical cancer: evidence from a meta-analysis.Tissue-based class control: the other side of tolerance.
P2860
Q26782895-74AEA388-6BD9-430F-A25E-BFA67832CA1EQ26852802-2AED17EB-DBC2-4EC4-99AD-3D36AEB8FA10Q28741414-942F0E19-01FF-4BC3-BDF5-DE6C9C43AD36Q33579574-1C232BD2-E8F9-4A87-96DF-61F2CEE04699Q33841936-39297774-C916-49F4-8380-06F6D1B43036Q33994168-A564553D-E834-4050-991A-362CC9945DBAQ34009730-849FDA38-AF7E-4FD9-A32C-8D21327C8C60Q34217243-BC980324-53F9-4F31-BA61-C9B97B0F6B19Q34566740-731D4DB0-BECD-4B5D-9FB0-AEA11BC7BE8DQ34791186-2E8C7559-307D-4478-957D-F8538CDFB9FAQ34992210-C244E938-17EE-44A9-9918-EF0D848BC116Q35097949-04D6831A-0723-4E23-81AF-2A47A9FA5FD9Q35221160-A68E10A2-696F-44D3-8973-8402C34AA0F8Q35271742-B0BDC556-F6DB-4510-8F5C-6EAB2BEF0F78Q35847696-7953914B-C492-476A-BF0F-8FD570BBCF21Q35893369-FEA1BD02-2667-4B86-ADFD-6B0C3AB4F976Q36219516-22AE261C-FA82-4101-B30E-3D407C162055Q36691088-AFA6FFAE-26D3-4C03-9100-E56AB859245DQ36774486-C52D03B1-89AD-45BE-BC82-1FB3E2C9F7CBQ36825505-BB7FA37E-0C6B-450F-B5A0-C5832982CC38Q36911426-BB012AF9-748A-4297-8FAB-C890322509E0Q37034919-EDFEE486-53D1-4684-9353-2DC100BA1080Q37043940-F87693CC-60DF-463D-BA31-7F3F0E39EAF8Q37055402-DAB623E8-56E2-4C5E-AFF2-D7162F9CB8FDQ37358408-E8B227DE-2108-4E25-BBD9-787D9418A1CCQ37863548-5E4089E3-9D36-4C32-B247-B601B5408CDFQ38113726-C8DF1C66-6434-46C9-B627-1007B3DE345CQ38526096-102802C6-572D-4CB7-B015-D2D9E39AC18DQ38627998-4BA084F8-DD75-4EAD-95FF-13A50EB3DED9Q39013916-274FC085-DF54-4EA5-A06A-230901D14FA3Q39239026-E38E6E8E-A4E5-49D1-A1B2-D73358A44270Q40502050-7FE36343-20F6-4626-976E-4978C5C25967Q41787771-2BF5200E-294D-4675-839E-04173C07BDC3Q42203980-88F40C40-4AA6-423F-B9C8-B9177BB01B9AQ42560166-D16F6BC3-245E-4AFF-B289-321C5E56BC2AQ43035535-92A2428E-11B4-4E67-9925-9FF5E11FCD34Q45355916-9FA37EFB-69AB-4FA2-983C-B613941B886BQ47103934-A7748C9B-497F-4139-928A-7E917189B496Q47896302-A2B3521A-7CDD-4B32-8654-39811BC6642CQ51018682-8DF9FDEC-F49E-4444-8393-56143998D43D
P2860
A vision of cell death: Fas ligand and immune privilege 10 years later.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A vision of cell death: Fas ligand and immune privilege 10 years later.
@ast
A vision of cell death: Fas ligand and immune privilege 10 years later.
@en
type
label
A vision of cell death: Fas ligand and immune privilege 10 years later.
@ast
A vision of cell death: Fas ligand and immune privilege 10 years later.
@en
prefLabel
A vision of cell death: Fas ligand and immune privilege 10 years later.
@ast
A vision of cell death: Fas ligand and immune privilege 10 years later.
@en
P2860
P1476
A vision of cell death: Fas ligand and immune privilege 10 years later.
@en
P2093
Thomas A Ferguson
Thomas S Griffith
P2860
P304
P356
10.1111/J.1600-065X.2006.00430.X
P577
2006-10-01T00:00:00Z